What you are working on right now?
We’ve just signed our first deal – the first revenue into Ferryx. This is an ‘option to license’ with a period of exclusivity of 9 months to conductdo trials of our lead product in chickens. This project is looking at reducing the incidencestance and severity of infectious disease in chickens. By using our product in the chicken feed, the hope is it will improve productivity, giving a better feed conversion ratio – less feed, more chicken.
Trials are starting in late Spring as we will be controlling the manufacturing of the product, as well as acting in a consultancy capacity. The goal of the project is to license the Ferryx product and develop it into a chicken feed product in 2022.
In terms of the IBD/IBS product, we’re actively looking for investment of £270,000 to develop our regulatory strategy and clinical trial design. Our plan is to start clinical trials in patients with IBD in 2023.
Tell us about your journey with Future Space
We moved into the shared office at Future Space in 2019, and at that time we had a licensing agreement fall through. I worked with the Launch Space team to develop my pitch, and Future Space introduced us to the Oxford Investment Opportunity Network (OION) to attend one of their pitching events. When we needed money and had no idea where to turn, it was great to turn to the Future Space support services and their connections.
Being a part of a bigger community and a network of peers with connections and experience is so valuable. I’ve got a lot from the network and events at Future Space, like weekly Founders Forum, beer and pizza evenings (pre-covid!), and business support workshops. The advisory space initiative is another fantastic resource – I’ve already made use of PR & Marketing, Legal, and Business Development advisory sessions, and it’s comforting to know it’s there to book when I need it.
Ultimately, it’s the network of people that has been the biggest benefit to us.